ClinicalTrialsFinder
RecruitingNot ApplicableNCT06617013

GERD in Children With Cystic Fibrosis

Characteristics of Gastroesophageal Reflux in Children With Cystic Fibrosis

Sponsor

Duke University

Enrollment

20 participants

Start Date

Oct 23, 2024

Study Type

INTERVENTIONAL

Conditions

GERD in ChildrenCystic Fibrosis in Children

Summary

The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.

Eligibility

Min Age: 2 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Discontinuation of GERD therapy for people with cystic fibrosis in children and gerd in children. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDiscontinuation of GERD therapy

GERD therapy will be discontinued at time of enrollment.

Locations(1)

Duke University Hospital

Durham, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06617013

Related Trials

19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

NCT060667231 location

Sinus Disease in Young Children With Cystic Fibrosis

NCT061916406 locations

Physical Impairments in Children With Cystic Fibrosis

NCT069846791 location

Feasibility of Cough Monitoring in Children

NCT065871261 location

Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis

NCT062845771 location